Clinical Trials Browser

NCT06410534 2025-09-11

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Phase 1 Withdrawn

CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

Clinical Trials

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

CheckMate 79X

SALIENT

CERAD-IMMUNE

Yervoy Pregnancy Surveillance Study

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

CINDI

CheckMate 7UA

BENEFIT

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

ISILI

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

CheckMate 955

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Ipilimumab and GMCSF Immunotherapy for Prostate Cancer

Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma